Immatics N.V. Price & Performance (IMTX)

Immatics (NASDAQ:IMTX) experienced a 13% rise in its share price over the past week, adding $66 million to its market capitalization. However, this comes after a tough year for the company, with shares declining 61% over the last 12 months. Investors are closely monitoring its revenue growth, which rose 53% year-over-year.1

Immatics is expected to release its latest earnings report on March 20. Analysts predict a loss of $0.03 per share and revenue of $16.16 million for the quarter. The company’s stock currently trades at $4.55, with a market cap of $543.07 million. Its 52-week high stands at $13.77.2

Institutional investors have been active in adjusting their positions in Immatics. Y Intercept Hong Kong Ltd recently acquired 29,624 shares valued at $211,000. Other firms, including Point72 Asset Management and abrdn plc, have also increased their holdings, indicating growing interest in the biopharmaceutical company.3